Leveraging Lymphatic System Targeting in Systemic Lupus Erythematosus for Improved Clinical Outcomes

Overview

Journal Pharmacol Rev

Specialty Pharmacology

Date 2024 Feb 13

PMID 38351070

Authors

K T Babalola

M Arora

R Ganugula

S K Agarwal

C Mohan

M N V Ravi Kumar

Affiliations

Soon will be listed here.

Abstract

The role of advanced drug delivery strategies in drug repositioning and minimizing drug attrition rates, when applied early in drug discovery, is poised to increase the translational impact of various therapeutic strategies in disease prevention and treatment. In this context, drug delivery to the lymphatic system is gaining prominence not only to improve the systemic bioavailability of various pharmaceutical drugs but also to target certain specific diseases associated with the lymphatic system. Although the role of the lymphatic system in lupus is known, very little is done to target drugs to yield improved clinical benefits. In this review, we discuss recent advances in drug delivery strategies to treat lupus, the various routes of drug administration leading to improved lymph node bioavailability, and the available technologies applied in other areas that can be adapted to lupus treatment. Moreover, this review also presents some recent findings that demonstrate the promise of lymphatic targeting in a preclinical setting, offering renewed hope for certain pharmaceutical drugs that are limited by efficacy in their conventional dosage forms. These findings underscore the potential and feasibility of such lymphatic drug-targeting approaches to enhance therapeutic efficacy in lupus and minimize off-target effects of the pharmaceutical drugs. SIGNIFICANCE STATEMENT: The World Health Organization estimates that there are currently 5 million humans living with some form of lupus. With limited success in lupus drug discovery, turning to effective delivery strategies with existing drug molecules, as well as those in the early stage of discovery, could lead to better clinical outcomes. After all, effective delivery strategies have been proven to improve treatment outcomes.

Citing Articles

Lymph node targeting of cyclosporine ameliorates ocular manifestations in a mouse model of systemic lupus erythematosus (SLE) via PD-L1.

Ganugula R, Babalola K, Heyns I, Arora M, Agarwal S, Mohan C Nano Today. 2024; 57.

PMID: 38911970 PMC: 11192230. DOI: 10.1016/j.nantod.2024.102359.

References

Chang D, Lan J, Lin H, Luo S . Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002; 46(11):2924-7. DOI: 10.1002/art.10615. View

Fasano S, Pierro L, Pantano I, Iudici M, Valentini G . Longterm Hydroxychloroquine Therapy and Low-dose Aspirin May Have an Additive Effectiveness in the Primary Prevention of Cardiovascular Events in Patients with Systemic Lupus Erythematosus. J Rheumatol. 2017; 44(7):1032-1038. DOI: 10.3899/jrheum.161351. View

Wang J, Gan M . DNA Nanoflowers' Amelioration of Lupus Symptoms in Mice via Blockade of TLR7/9's Signal. Int J Mol Sci. 2022; 23(24). PMC: 9784230. DOI: 10.3390/ijms232416030. View

Tzeng H, Chyuan I . Immunometabolism in systemic lupus erythematosus: Relevant pathogenetic mechanisms and potential clinical applications. J Formos Med Assoc. 2021; 120(9):1667-1675. DOI: 10.1016/j.jfma.2021.03.019. View

Flexner C, Owen A, Siccardi M, Swindells S . Long-acting drugs and formulations for the treatment and prevention of HIV infection. Int J Antimicrob Agents. 2020; 57(1):106220. PMC: 7790856. DOI: 10.1016/j.ijantimicag.2020.106220. View

Woo J, Parks C, Jacobsen S, Costenbader K, Bernatsky S . The role of environmental exposures and gene-environment interactions in the etiology of systemic lupus erythematous. J Intern Med. 2022; 291(6):755-778. DOI: 10.1111/joim.13448. View

Hua Y, Wang Z, Wang D, Lin X, Liu B, Zhang H . Key Factor Study for Generic Long-Acting PLGA Microspheres Based on a Reverse Engineering of Vivitrol. Molecules. 2021; 26(5). PMC: 7975983. DOI: 10.3390/molecules26051247. View

Yin Y, Yang J, Pan Y, Guo Z, Gao Y, Huang L . Chylomicrons-Simulating Sustained Drug Release in Mesenteric Lymphatics for the Treatment of Crohn's-Like Colitis. J Crohns Colitis. 2020; 15(4):631-646. DOI: 10.1093/ecco-jcc/jjaa200. View

Witt M, Grunke M, Proft F, Baeuerle M, Aringer M, Burmester G . Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) - results from a nationwide cohort in Germany (GRAID). Lupus. 2013; 22(11):1142-9. DOI: 10.1177/0961203313503912. View

10.

Ostensen M, Villiger P . Nonsteroidal anti-inflammatory drugs in systemic lupus erythematosus. Lupus. 2000; 9(8):566-72. DOI: 10.1191/096120300678828794. View

11.

Permana A, Tekko I, McCrudden M, Anjani Q, Ramadon D, McCarthy H . Solid lipid nanoparticle-based dissolving microneedles: A promising intradermal lymph targeting drug delivery system with potential for enhanced treatment of lymphatic filariasis. J Control Release. 2019; 316:34-52. DOI: 10.1016/j.jconrel.2019.10.004. View

12.

Fanouriakis A, Bertsias G . Changing paradigms in the treatment of systemic lupus erythematosus. Lupus Sci Med. 2019; 6(1):e000310. PMC: 6519431. DOI: 10.1136/lupus-2018-000310. View

13.

Singh R, Hahn B, S Bischoff D . Interferon Genes Are Influenced by 17β-Estradiol in SLE. Front Immunol. 2021; 12:725325. PMC: 8558410. DOI: 10.3389/fimmu.2021.725325. View

14.

Fava A, Petri M . Systemic lupus erythematosus: Diagnosis and clinical management. J Autoimmun. 2018; 96:1-13. PMC: 6310637. DOI: 10.1016/j.jaut.2018.11.001. View

15.

Stevens D, Adiseshaiah P, Dasa S, Potter T, Skoczen S, Snapp K . Application of a Scavenger Receptor A1-Targeted Polymeric Prodrug Platform for Lymphatic Drug Delivery in HIV. Mol Pharm. 2020; 17(10):3794-3812. PMC: 7861197. DOI: 10.1021/acs.molpharmaceut.0c00562. View

16.

Alamilla-Sanchez M, Alcala-Salgado M, Alonso-Bello C, Fonseca-Gonzalez G . Mechanism of Action and Efficacy of Immunosupressors in Lupus Nephritis. Int J Nephrol Renovasc Dis. 2021; 14:441-458. PMC: 8675090. DOI: 10.2147/IJNRD.S335371. View

17.

Mitchell M, Billingsley M, Haley R, Wechsler M, Peppas N, Langer R . Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2020; 20(2):101-124. PMC: 7717100. DOI: 10.1038/s41573-020-0090-8. View

18.

Xin Y, Zhang B, Zhao J, Liu Q, Yin H, Lu Q . Animal models of systemic lupus erythematosus and their applications in drug discovery. Expert Opin Drug Discov. 2022; 17(5):489-500. DOI: 10.1080/17460441.2022.2050691. View

19.

Otomo K, Koga T, Mizui M, Yoshida N, Kriegel C, Bickerton S . Cutting Edge: Nanogel-Based Delivery of an Inhibitor of CaMK4 to CD4+ T Cells Suppresses Experimental Autoimmune Encephalomyelitis and Lupus-like Disease in Mice. J Immunol. 2015; 195(12):5533-7. PMC: 4670795. DOI: 10.4049/jimmunol.1501603. View

20.

Rostamzadeh D, Razavi S, Esmaeili S, Dolati S, Ahmahi M, Sadreddini S . Application of nanoparticle technology in the treatment of Systemic lupus erythematous. Biomed Pharmacother. 2016; 83:1154-1163. DOI: 10.1016/j.biopha.2016.08.020. View